170 related articles for article (PubMed ID: 36970726)
41. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
42. MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis.
Yang Y; Qiu R; Weng Q; Xu Z; Song J; Zhao S; Meng M; Zhang D; Kong C; Wang H; Xu M; Zhao Z; Ji J
Cancer Res Treat; 2023 Jul; 55(3):778-803. PubMed ID: 36701842
[TBL] [Abstract][Full Text] [Related]
43. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
44. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells.
Kim JH; Sharma A; Dhar SS; Lee SH; Gu B; Chan CH; Lin HK; Lee MG
Cancer Res; 2014 Mar; 74(6):1705-17. PubMed ID: 24491801
[TBL] [Abstract][Full Text] [Related]
45. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle.
Mishra BP; Ansari KI; Mandal SS
FEBS J; 2009 Mar; 276(6):1629-40. PubMed ID: 19220463
[TBL] [Abstract][Full Text] [Related]
46. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
47. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.
Patel A; Dharmarajan V; Vought VE; Cosgrove MS
J Biol Chem; 2009 Sep; 284(36):24242-56. PubMed ID: 19556245
[TBL] [Abstract][Full Text] [Related]
48. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
[TBL] [Abstract][Full Text] [Related]
49. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
Grunt TW; Mariani GL
Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
[TBL] [Abstract][Full Text] [Related]
50. PI3K Inhibitors in Breast Cancer Therapy.
Ellis H; Ma CX
Curr Oncol Rep; 2019 Dec; 21(12):110. PubMed ID: 31828441
[TBL] [Abstract][Full Text] [Related]
51. Protein kinase Msk1 physically and functionally interacts with the KMT2A/MLL1 methyltransferase complex and contributes to the regulation of multiple target genes.
Wiersma M; Bussiere M; Halsall JA; Turan N; Slany R; Turner BM; Nightingale KP
Epigenetics Chromatin; 2016; 9():52. PubMed ID: 27895715
[TBL] [Abstract][Full Text] [Related]
52. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
Ma YS; Wu TM; Qian B; Liu YS; Ding H; Fan MM; Liu JB; Yu F; Wang HM; Shi Y; Gu LP; Li L; Tian LL; Wang PY; Wang GR; Wu ZJ; Zou QF; Ling CC; Fu D
J Cell Mol Med; 2021 Apr; 25(8):4040-4052. PubMed ID: 33621431
[TBL] [Abstract][Full Text] [Related]
53. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance.
Zou JX; Duan Z; Wang J; Sokolov A; Xu J; Chen CZ; Li JJ; Chen HW
Mol Cancer Res; 2014 Apr; 12(4):539-49. PubMed ID: 24391143
[TBL] [Abstract][Full Text] [Related]
54. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
55. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
56. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
[TBL] [Abstract][Full Text] [Related]
57. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
58. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
[TBL] [Abstract][Full Text] [Related]
59. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
60. The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
Wang LH; Aberin MAE; Wu S; Wang SP
Biochem Soc Trans; 2021 Jun; 49(3):1041-1054. PubMed ID: 34156443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
